GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Introduction: Tamoxifen is widely used to treat hormone-dependent breast cancer, but its therapeutic benefit is limited by the development of drug resistance. Here, we investigated the role of estrogen G-protein coupled receptor 30 (GPR30) on Tamoxifen resistance in breast cancer. Methods: Primary tumors (PTs) of breast cancer and corresponding metastases (MTs) were used to evaluate the expression of GPR30 and epidermal growth factor receptor (EGFR) immunohistochemically. Tamoxifen-resistant (TAM-R) subclones derived from parent MCF-7 cells were used to investigate the role of GPR30 in the development of tamoxifen resistance, using MTT assay, western blot, RT-PCR, immunofluorescence, ELISA and flow cytometry. TAM-R xenografts were established to assess anti-tumor effects of combination therapy with GPR30 antagonist G15 plus 4-hydroxytamoxifen (Tam), using tumor volume measurement and Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL). Results: In 53 human breast cancer specimens, GPR30 expression in MTs increased compared to matched PTs; in MTs, the expression patterns of GPR30 and EGFR were closely related. Compared to parent MCF-7 cells, TAM-R cells had greater growth responses to 17β-estradiol (E2), GPR30 agonist G1 and Tam, and significantly higher activation of Mitogen-activated protein (MAP) kinases; but this increased activity was abolished by G15 or AG1478. In TAM-R cells, GPR30 cell-surface translocation facilitated crosstalk with EGFR, and reduced cAMP generation, attenuating inhibition of EGFR signaling. Combination therapy both promoted apoptosis in TAM-R cells and decreased drug-resistant tumor progression. Conclusions: Long-term endocrine treatment facilitates the translocation of GPR30 to cell surfaces, which interferes with the EGFR signaling pathway; GPR30 also attenuates the inhibition of MAP kinases. These factors contribute to tamoxifen resistance development in breast cancer. Combination therapy with GPR30 inhibitors and tamoxifen may provide a new therapeutic option for drug-resistant breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The unfolding stories of GPR30, a new membrane-bound estrogen receptor
Maggiolini, M., & Picard, D. (2010) · Journal of Endocrinology · doi:10.1677/joe-09-0242 · Cited by 360 · cited 8×
“Increased Erk1/2activation was associated with intense GPR30/EGFR crosstalk in TAM-R cells Because activated GPR30 at the cell membrane promotes HB-EGF release to activate the EGFR signaling pathway, resulting in phosphorylation of Erk1/2 in breast cancer cells, and TAM-R cells (as described above) increase activation…”
BackgroundInfluentialMechanisms of estrogen signaling and gene expression via GPR30
Prossnitz, E. R., & Maggiolini, M. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.03.026 · Cited by 346
Cited by
Prossnitz, E. R., & Arterburn, J. B. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009712 · Cited by 258
The G protein-coupled oestrogen receptor GPER in health and disease: an update
Prossnitz, E. R., & Barton, M. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00822-7 · Cited by 231
Hernández-Silva, C. D., Villegas-Pineda, J. C., & Pereira-Suárez, A. L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00544 · Cited by 74
Gilligan, L. C., Gondal, A., Tang, V., Hussain, M. T., Arvaniti, A., Hewitt, A.-M., & Foster, P. A. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00103 · Cited by 32
“However, it has recently been shown that tamoxifen may act as a GPER agonist in tamoxifen-resistant tumors (Mo et al., 2013).”
BackgroundLiu, L., Zhou, Y., Liu, J., Zhang, X., He, C., Zeng, X., Dejenie, R., Zeb, U., Zeng, Q., Liu, L., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07005-0 · Cited by 13
“However, they may promote cell proliferation in certain cell types while inducing apoptosis in others [259, 260].”
Metadata
- Authors
- Mo, Z., Liu, M., Yang, F., Luo, H., Li, Z., Tu, G., & Yang, G.
- Venue
- Breast Cancer Research
- Published
- 2013-11-29
- Volume
- 15
- Issue
- 6
- Pages
- R114-R114
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W2128413527
- Cited by
- 134
- References
- 2
- FWCI
- 6.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.